91短视频

BRIDGEWATER, N.J. 鈥� Nestl茅 Health Science has joined the Microbiome Therapeutics Innovation Group (MTIG), aligning the company with a growing industry effort to advance regulatory clarity and commercial pathways for microbiome-based therapies.

The coalition, which brings together companies developing FDA-approved microbiome therapeutics, focuses on improving the regulatory, investment, and market environment to accelerate innovation and patient access. Nestl茅 said its participation underscores a broader commitment to science-driven development in a category that is gaining traction across pharmaceutical and nutrition-adjacent healthcare segments.

Krys Araujo-Torres, MD, MPP, global head of medical, science, and regulatory at Nestl茅 Health Science, will represent the company within MTIG, contributing clinical, regulatory, and real-world evidence expertise to the group鈥檚 policy and education initiatives.

鈥淛oining MTIG reflects our commitment to responsible, science-led advancement of microbiome therapeutics,鈥� said Luis Briz, president of professional health at Nestl茅 Health Science. 鈥淲e aim to support clear, pragmatic pathways that help bring safe and effective microbiome medicines to more patients.鈥�

Nestl茅鈥檚 involvement builds on its work with Seres Therapeutics to commercialize VOWST, an oral live biotherapeutic product approved by the U.S. Food and 91短视频 Administration in 2023 to prevent recurrence of Clostridioides difficile infection in adults after antibacterial treatment. The product marked a regulatory milestone as the first oral therapy of its kind, helping establish a framework for future microbiome-based medicines.

鈥淎s we continue to steward VOWST and generate additional evidence in line with evolving clinical standards, we look forward to contributing insights to MTIG鈥檚 agenda,鈥� Araujo-Torres said.

The move comes as interest in microbiome therapeutics expands, with stakeholders seeking clearer regulatory pathways and reimbursement models. Industry groups such as MTIG have increasingly shaped policy discussions, particularly as live biotherapeutic products move from early research into commercial deployment.

For Nestl茅 Health Science, MTIG membership signals continued investment in bridging nutrition science and biopharmaceutical innovation, positioning the company within a fast-growing segment at the intersection of gut health, precision medicine and advanced therapeutics.